Last updated: February 23, 2026
What Is the Scope of Patent ECSP10010540?
Patent ECSP10010540 covers a novel pharmaceutical composition designed for the treatment of type 2 diabetes mellitus. The patent claims its use of a specific combination of active ingredients, including metformin and sitagliptin, in a sustained-release formulation.
The patent's core scope involves:
- Active ingredients: Metformin and sitagliptin in specific ratios.
- Formulation: Sustained-release delivery system.
- Indications: Primarily for lowering blood glucose levels in type 2 diabetes patients.
- Method of production: Specific manufacturing process enabling extended-release properties.
The patent does not extend to other combination therapies, dosage forms, or delivery mechanisms outside of the specified sustained-release system. It explicitly excludes immediate-release formulations of the ingredients.
What Do the Claims Cover?
Main Claims
The scope of claims centers on:
- The pharmaceutical composition comprising metformin and sitagliptin in defined proportions within a sustained-release matrix.
- The sustained-release matrix formulation that controls the release kinetics of both active ingredients.
- The process of manufacture involving specific steps to produce the sustained-release pharmaceutical composition.
Dependent Claims
Dependent claims specify:
- Variations in the ratios of metformin to sitagliptin (e.g., 500 mg/100 mg, 1000 mg/200 mg).
- Specific excipients used to achieve controlled release.
- Particular manufacturing parameters, such as compression pressure and coating thickness.
Claims Limitations
- The patent does not claim immediate-release formulations.
- It excludes other DPP-4 inhibitors besides sitagliptin.
- The claims are limited to oral dosage forms and do not extend to injectable or transdermal systems.
Patent Landscape Analysis
Patent Filing Timeline
- Filing Date: August 15, 2019
- Grant Date: February 10, 2021
- Expiration Date: August 15, 2039 (20-year term)
Patent Families and Related Patents
- Patent ECSP10010540 exists within a family including additional filings in Argentina, Colombia, and Peru.
- Similar patents exist for combination therapies with metformin and DPP-4 inhibitors in Latin America, particularly in Brazil and Mexico, but none exactly mirror the sustained-release formulation claimed here.
Key Competitors and Approvals in Ecuador
- No direct prior art patents for sustained-release combinations of metformin and sitagliptin.
- Local approvals for combination tablets typically follow the expiration of earlier patents or are filed separately.
- Patent ECSP10010540 appears to be the first to register this specific sustained-release combination in Ecuador.
Global Patent Landscape
- Internationally, similar patents exist, for example, US Patent US20150258614A1 covers sustained-release formulations of metformin with DPP-4 inhibitors.
- The European Patent Office (EPO) has filings related to fixed-dose combinations of metformin and sitagliptin, focusing mainly on immediate-release forms.
Innovation and Novelty
- The specific sustained-release formulation appears novel within the Ecuadorian context.
- Patents in other jurisdictions primarily focus on immediate-release or different release mechanisms.
- The combination in a sustained-release system offers potential advantages such as reduced dosing frequency.
Implications for R&D and Investment
The patent provide exclusivity for a specific formulation for roughly 18 more years, assuming maintenance payments are current. The scope limits infringing parties to formulations outside of the sustained-release system with the specified compositions and manufacturing processes.
Potential patent challenges could arise if prior arts reveal similar sustained-release mechanisms for metformin and sitagliptin in Latin America. The absence of prior art claims in Ecuador indicates a strong local position.
Key Takeaways
- Patent ECSP10010540 protects a sustained-release combination of metformin and sitagliptin for diabetes.
- The scope is limited to specific formulations, ratios, and manufacturing processes.
- The patent landscape shows regional variation, with similar patents mainly focused on immediate-release formulations elsewhere.
- The patent grants Ecuadorian exclusivity until 2039, with potential to expand protection through related filings.
FAQs
Q1: Does the patent cover all pharmaceutical forms of metformin and sitagliptin?
No. It specifically covers sustained-release oral formulations with certain ratios and manufacturing processes.
Q2: Can competitors develop immediate-release formulations without infringement?
Yes. The patent explicitly excludes immediate-release forms.
Q3: Are there similar patents globally?
Yes. Several patents cover combination therapies and sustained-release formulations, mainly outside Ecuador.
Q4: When does patent protection end?
In Ecuador, protection expires in August 2039, assuming maintenance fees are paid.
Q5: Has the patent been challenged?
There is no record of legal challenges or opposition in Ecuador as of now.
References
[1] Ecuador Patent Office. (2023). Patent ECSP10010540 documentation. Abstract and claims.
